ITMI20092117A1 - Struttura del cristallo del complesso di timidilato sintetasi (ts) con un ligando - Google Patents
Struttura del cristallo del complesso di timidilato sintetasi (ts) con un ligando Download PDFInfo
- Publication number
- ITMI20092117A1 ITMI20092117A1 IT002117A ITMI20092117A ITMI20092117A1 IT MI20092117 A1 ITMI20092117 A1 IT MI20092117A1 IT 002117 A IT002117 A IT 002117A IT MI20092117 A ITMI20092117 A IT MI20092117A IT MI20092117 A1 ITMI20092117 A1 IT MI20092117A1
- Authority
- IT
- Italy
- Prior art keywords
- ligand
- hts
- protein
- complex
- binding site
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title claims description 103
- 239000013078 crystal Substances 0.000 title claims description 54
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 38
- 102000004169 proteins and genes Human genes 0.000 claims description 28
- 108090000623 proteins and genes Proteins 0.000 claims description 28
- 238000006471 dimerization reaction Methods 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 13
- 101000809797 Homo sapiens Thymidylate synthase Proteins 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 11
- 101000653005 Homo sapiens Thromboxane-A synthase Proteins 0.000 claims description 10
- 230000001580 bacterial effect Effects 0.000 claims description 10
- 230000003993 interaction Effects 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 230000003197 catalytic effect Effects 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 238000002424 x-ray crystallography Methods 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 229940041181 antineoplastic drug Drugs 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 5
- 230000000259 anti-tumor effect Effects 0.000 claims description 4
- 230000035945 sensitivity Effects 0.000 claims description 4
- 230000002194 synthesizing effect Effects 0.000 claims description 4
- 238000004458 analytical method Methods 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000000205 computational method Methods 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 108010022394 Threonine synthase Proteins 0.000 description 106
- 102000005497 Thymidylate Synthase Human genes 0.000 description 106
- 125000004429 atom Chemical group 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 22
- 239000000243 solution Substances 0.000 description 15
- 239000003112 inhibitor Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 238000013461 design Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 239000000539 dimer Substances 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 238000002441 X-ray diffraction Methods 0.000 description 8
- 235000014304 histidine Nutrition 0.000 description 8
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 7
- 239000000710 homodimer Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
- 238000013480 data collection Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 125000004434 sulfur atom Chemical group 0.000 description 5
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 238000002288 cocrystallisation Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical class [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical group [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 102100025698 Cytosolic carboxypeptidase 4 Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 101000932590 Homo sapiens Cytosolic carboxypeptidase 4 Proteins 0.000 description 2
- 101001033003 Mus musculus Granzyme F Proteins 0.000 description 2
- 101100386053 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cys-3 gene Proteins 0.000 description 2
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000011549 crystallization solution Substances 0.000 description 2
- 238000002050 diffraction method Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 230000009088 enzymatic function Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 125000000101 thioether group Chemical group 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 101100533230 Caenorhabditis elegans ser-2 gene Proteins 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 206010011953 Decreased activity Diseases 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108010025076 Holoenzymes Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102100025169 Max-binding protein MNT Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 238000002447 crystallographic data Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000037360 nucleotide metabolism Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 230000009712 regulation of translation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- -1 sulfate anions Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y201/00—Transferases transferring one-carbon groups (2.1)
- C12Y201/01—Methyltransferases (2.1.1)
- C12Y201/01045—Thymidylate synthase (2.1.1.45)
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1007—Methyltransferases (general) (2.1.1.)
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/50—Molecular design, e.g. of drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Theoretical Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Evolutionary Biology (AREA)
- Computing Systems (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT002117A ITMI20092117A1 (it) | 2009-12-01 | 2009-12-01 | Struttura del cristallo del complesso di timidilato sintetasi (ts) con un ligando |
PCT/IB2010/055503 WO2011067715A1 (fr) | 2009-12-01 | 2010-11-30 | Structure cristalline d'un complexe de thymidylate synthase (ts) avec un ligand |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT002117A ITMI20092117A1 (it) | 2009-12-01 | 2009-12-01 | Struttura del cristallo del complesso di timidilato sintetasi (ts) con un ligando |
Publications (1)
Publication Number | Publication Date |
---|---|
ITMI20092117A1 true ITMI20092117A1 (it) | 2011-06-02 |
Family
ID=42055656
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IT002117A ITMI20092117A1 (it) | 2009-12-01 | 2009-12-01 | Struttura del cristallo del complesso di timidilato sintetasi (ts) con un ligando |
Country Status (2)
Country | Link |
---|---|
IT (1) | ITMI20092117A1 (fr) |
WO (1) | WO2011067715A1 (fr) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002072753A2 (fr) * | 2001-03-07 | 2002-09-19 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Peptides de thymidylate synthase se fixant a l'arnm de la thymidylate synthase |
-
2009
- 2009-12-01 IT IT002117A patent/ITMI20092117A1/it unknown
-
2010
- 2010-11-30 WO PCT/IB2010/055503 patent/WO2011067715A1/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002072753A2 (fr) * | 2001-03-07 | 2002-09-19 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Peptides de thymidylate synthase se fixant a l'arnm de la thymidylate synthase |
Non-Patent Citations (7)
Title |
---|
BERGER S H ET AL: "Effects of ligand binding and conformational switching on intracellular stability of human thymidylate synthase", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - PROTEINS & PROTEOMICS, ELSEVIER LNKD- DOI:10.1016/J.BBAPAP.2003.09.005, vol. 1696, no. 1, 14 January 2004 (2004-01-14), pages 15 - 22, XP004483641, ISSN: 1570-9639 * |
GIBSON LYDIA M ET AL: "The R163K mutant of human thymidylate synthase is stabilized in an active conformation: Structural asymmetry and reactivity of cysteine 195", BIOCHEMISTRY, vol. 47, no. 16, April 2008 (2008-04-01), pages 4636 - 4643, XP002577032, ISSN: 0006-2960 * |
LOVELACE LESLIE L ET AL: "Structure of human thymidylate synthase under low-salt conditions", ACTA CRYSTALLOGRAPHICA SECTION D: BIOLOGICAL CRYSTALLOGRAPHY, MUNKSGAARD PUBLISHERS LTD. COPENHAGEN, DK LNKD- DOI:10.1107/S0907444905005895, vol. 61, no. 5, 1 May 2005 (2005-05-01), pages 622 - 627, XP008121213, ISSN: 0907-4449 * |
LOVELACE LESLIE L ET AL: "Variants of human thymidylate synthase with loop 181-197 stabilized in the inactive conformation", PROTEIN SCIENCE,, vol. 18, no. 8, 1 August 2009 (2009-08-01), pages 1628 - 1636, XP002574294 * |
PRASANNA V ET AL: "Synthetic interface peptides as inactivators of multimeric enzymes: inhibitory and conformational properties of three fragments from Lactobacillus casei thymidylate synthase", BIOCHEMISTRY 12 MAY 1998,, vol. 37, no. 19, 12 May 1998 (1998-05-12), pages 6883 - 6893, XP002574293 * |
SOTRIFFER CHRISTOPH ET AL: "Identification and mapping of small-molecule binding sites in proteins: Computational tools for structure-based drug design.", FARMACO (LAUSANNE), vol. 57, no. 3, March 2002 (2002-03-01), pages 243 - 251, XP002577118, ISSN: 0014-827X * |
VOELLER D M ET AL: "The identification of thymidylate synthase peptide domains located in the interface region that bind thymidylate synthase mRNA", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US LNKD- DOI:10.1016/S0006-291X(02)02080-6, vol. 297, 1 July 2002 (2002-07-01), pages 24 - 31, XP002984377, ISSN: 0006-291X * |
Also Published As
Publication number | Publication date |
---|---|
WO2011067715A1 (fr) | 2011-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Haltia et al. | Crystal structure of nitrous oxide reductase from Paracoccus denitrificans at 1.6 A resolution | |
Sato et al. | Structural basis for specific cleavage of Lys 63-linked polyubiquitin chains | |
Sánchez-Barrena et al. | The structure of the Arabidopsis thaliana SOS3: molecular mechanism of sensing calcium for salt stress response | |
Drozd et al. | Crosstalk of the structural and zinc buffering properties of mammalian metallothionein-2 | |
Cupp-Vickery et al. | Crystal structure of IscA, an iron-sulfur cluster assembly protein from Escherichia coli | |
Fang et al. | Structural insight into plant programmed cell death mediated by BAG proteins in Arabidopsis thaliana | |
Xie et al. | Structural insights into the assembly of human translesion polymerase complexes | |
Loris et al. | Crystal structure determination and refinement at 2.3-. ANG. resolution of the lentil lectin | |
Rupert et al. | A new DNA-binding motif in the Skn-1 binding domain–DNA complex | |
Liang et al. | Crystal structure of P13K SH3 domain at 2.0 Å resolution | |
Petrova et al. | Structure and function of the N-terminal domain of the yeast telomerase reverse transcriptase | |
Boerema et al. | Total synthesis by modern chemical ligation methods and high resolution (1.1 Å) X‐ray structure of ribonuclease A | |
Gong et al. | Structure of the HECT domain of human WWP2 | |
Harjes et al. | The crystal structure of human PAPS synthetase 1 reveals asymmetry in substrate binding | |
Taskinen et al. | High resolution crystal structures of unliganded and liganded human liver ACBP reveal a new mode of binding for the acyl‐CoA ligand | |
Rudiño-Piñera et al. | The solution and crystal structures of a module pair from the Staphylococcus aureus-binding site of human fibronectin—a tale with a twist | |
Geethanandan et al. | X-ray structure of a galactose-specific lectin from Spatholobous parviflorous | |
Tishchenko et al. | Protein–RNA affinity of ribosomal protein L1 mutants does not correlate with the number of intermolecular interactions | |
Chen et al. | Structural insight into the conformational change of alcohol dehydrogenase from Arabidopsis thaliana L. during coenzyme binding | |
Merlino et al. | The buried diversity of bovine seminal ribonuclease: shape and cytotoxicity of the swapped non-covalent form of the enzyme | |
Dowierciał et al. | Crystal Structure of Mouse Thymidylate Synthase in Tertiary Complex with dUMP and Raltitrexed Reveals N‐Terminus Architecture and Two Different Active Site Conformations | |
Conlan et al. | The novel 2Fe–2S outer mitochondrial protein mitoNEET displays conformational flexibility in its N-terminal cytoplasmic tethering domain | |
Johansson et al. | X-ray structure of domain I of the proton-pumping membrane protein transhydrogenase from Escherichia coli | |
ITMI20092117A1 (it) | Struttura del cristallo del complesso di timidilato sintetasi (ts) con un ligando | |
Huang et al. | Structural features of the single-stranded DNA-binding protein MoSub1 from Magnaporthe oryzae |